Last reviewed · How we verify

NCT04875364: ExPRESSION

Do Endotypes Predict Response and Sequelae in OSA Patients

Recruiting now Phase 2 Last updated 2 October 2024
What this trial tests

Phase 2 trial testing Eszopiclone in Obstructive Sleep Apnea in 200 participants. Currently enrolling.

Timeline
1 August 2020
Primary endpoint
1 January 2027
1 January 2027

Quick facts

Lead sponsorUniversity of California, San Diego
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment200
Start date1 August 2020
Primary completion1 January 2027
Estimated completion1 January 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Diego

Who can join

Adults 21 to 65, any sex, with Obstructive Sleep Apnea or Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate why some people have Obstructive Sleep Apnea (OSA) and how the underlying cause may relate to OSA manifestations (including sleepiness and high blood pressure) and response to different therapeutic approaches (ie CPAP, eszopiclone, and supplemental oxygen). Understanding why someone has OSA could affect how best to treat that individual, but may also have an impact on what problems the disease might cause.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Eszopiclone

Trials testing the same drug.

Other recruiting trials for Obstructive Sleep Apnea

Currently open trials in the same condition.

Other University of California, San Diego trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04875364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing